CO6480995A2 - Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv - Google Patents
Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpvInfo
- Publication number
- CO6480995A2 CO6480995A2 CO12001297A CO12001297A CO6480995A2 CO 6480995 A2 CO6480995 A2 CO 6480995A2 CO 12001297 A CO12001297 A CO 12001297A CO 12001297 A CO12001297 A CO 12001297A CO 6480995 A2 CO6480995 A2 CO 6480995A2
- Authority
- CO
- Colombia
- Prior art keywords
- hpv
- prevention
- human
- pailoma
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La divulgación proporciona construcciones novedosas de proteína del virus de papiloma humano (HPV) y su uso en la prevención de la enfermedad por el HPV. Las construcciones son proteínas quiméricas que comprenden proteínas L1 con un péptido L2 de HPV insertado en la proteína L1. Estas proteínas quiméricas se pueden formular en composiciones inmunogénicas, por ejemplo, de vacuna, y se pueden formular opcionalmente con las vacunas basadas en HPV L1 VLP.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22035809P | 2009-06-25 | 2009-06-25 | |
US23988009P | 2009-09-04 | 2009-09-04 | |
US32210210P | 2010-04-08 | 2010-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6480995A2 true CO6480995A2 (es) | 2012-07-16 |
Family
ID=43014491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12001297A CO6480995A2 (es) | 2009-06-25 | 2012-01-04 | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv |
Country Status (20)
Country | Link |
---|---|
US (1) | US20120087937A1 (es) |
EP (1) | EP2445525A2 (es) |
JP (1) | JP2012530505A (es) |
KR (1) | KR20120098580A (es) |
CN (1) | CN102497880A (es) |
AU (1) | AU2010264695A1 (es) |
BR (1) | BRPI1014718A2 (es) |
CA (1) | CA2768172A1 (es) |
CL (1) | CL2011003271A1 (es) |
CO (1) | CO6480995A2 (es) |
CR (1) | CR20120026A (es) |
DO (1) | DOP2011000396A (es) |
EA (1) | EA022213B1 (es) |
IL (1) | IL217094A0 (es) |
MA (1) | MA33440B1 (es) |
MX (1) | MX2011013744A (es) |
PE (1) | PE20120563A1 (es) |
SG (1) | SG177269A1 (es) |
WO (1) | WO2010149752A2 (es) |
ZA (1) | ZA201109453B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102458440A (zh) * | 2009-04-10 | 2012-05-16 | 约翰·霍普金斯大学 | 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp) |
CA2850293C (en) * | 2011-12-01 | 2019-10-08 | University Of Cape Town | Hpv chimaeric particle |
JP2015514696A (ja) | 2012-03-18 | 2015-05-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ヒト・パピローマウイルスに対するワクチン接種方法 |
CN103864936B (zh) * | 2012-12-11 | 2018-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途 |
JPWO2014103608A1 (ja) * | 2012-12-25 | 2017-01-12 | 一般財団法人化学及血清療法研究所 | HPV/HBsキメラタンパク質を有効成分とするHPV感染症及び/又はB型肝炎用ワクチン |
CN104845985B (zh) * | 2014-02-18 | 2020-02-07 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒蛋白表达 |
CN104531741B (zh) * | 2014-08-22 | 2016-08-24 | 天津康希诺生物技术有限公司 | 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用 |
US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
WO2016065281A1 (en) * | 2014-10-24 | 2016-04-28 | Tim Ioannides | Cancer and skin lesion treatment |
DK3368068T3 (da) | 2015-10-30 | 2021-02-22 | Univ Copenhagen | Viruslignende partikler med effektiv epitopdisplay |
CN106831961B (zh) * | 2015-12-04 | 2019-11-05 | 厦门大学 | 一种人乳头瘤病毒58型l1蛋白的突变体 |
KR20180112043A (ko) * | 2016-02-27 | 2018-10-11 | 에이치피브이백스, 엘엘씨. | 백신을 사용하여 암 또는 피부 병변을 치료하기 위한 방법 및 조성물 |
CN107188967B (zh) * | 2016-03-15 | 2020-03-31 | 中国医学科学院基础医学研究所 | 一种乳头瘤病毒嵌合蛋白及其用途 |
CN107188966B (zh) * | 2016-03-15 | 2020-03-31 | 中国医学科学院基础医学研究所 | 一种乳头瘤病毒嵌合蛋白及其用途 |
CN109251235B (zh) * | 2017-07-14 | 2021-04-27 | 厦门大学 | 一种人乳头瘤病毒16型l1蛋白的突变体 |
JP7290258B2 (ja) * | 2018-09-26 | 2023-06-13 | 厦▲門▼大学 | ヒトパピローマウイルス51型のl1タンパク質の変異型 |
WO2021013067A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒6型l1蛋白 |
CN114127094B (zh) * | 2019-07-19 | 2024-04-26 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒58型l1蛋白 |
CN114127097A (zh) * | 2019-07-19 | 2022-03-01 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒56型l1蛋白 |
CN111944834A (zh) * | 2020-09-04 | 2020-11-17 | 吉林医药学院 | 人乳头瘤病毒16型表位嵌合l1的重组载体、重组蛋白、病毒样颗粒及其制备和应用 |
CN112300290B (zh) * | 2020-09-30 | 2022-04-01 | 北京康乐卫士生物技术股份有限公司 | 一种使用乳头瘤病毒类病毒颗粒递呈抗原的新型冠状病毒多肽疫苗 |
CN114716561B (zh) * | 2021-01-04 | 2024-03-12 | 中国医学科学院基础医学研究所 | 一种人乳头瘤病毒31型嵌合蛋白及其用途 |
CN114716562B (zh) * | 2021-01-04 | 2023-11-10 | 中国医学科学院基础医学研究所 | 一种人乳头瘤病毒58型嵌合蛋白及其用途 |
CN114716560B (zh) * | 2021-01-04 | 2024-02-02 | 中国医学科学院基础医学研究所 | 一种人乳头瘤病毒18型嵌合蛋白及其用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US7351533B2 (en) | 1997-09-05 | 2008-04-01 | Medimmune, Inc. | In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents |
PT1015561E (pt) | 1997-09-05 | 2006-11-30 | Medimmune Inc | Método in vitro para desorganização/reorganização de partículas semelhantes ao vírus papilomavírus (vlps) |
DK1012348T3 (da) | 1997-09-16 | 2002-10-14 | Innogenetics Nv | Detektion og identifikation af humant papillomavirus ved PCR og typespecifik revers hybridisering |
ES2284287T3 (es) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
WO2003014402A2 (en) | 2001-08-08 | 2003-02-20 | Glaxosmithkline Biologicals S.A. | Method for identification of type specific polynucleotide sequences |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
ATE424409T1 (de) * | 2002-05-17 | 2009-03-15 | Univ Cape Town | Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel |
GB0228715D0 (en) | 2002-12-09 | 2003-01-15 | Glaxosmithkline Biolog Sa | Vaccine |
CA2596698C (en) | 2005-02-01 | 2017-05-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies |
JP4825958B2 (ja) * | 2005-08-10 | 2011-11-30 | 財団法人ヒューマンサイエンス振興財団 | 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原 |
WO2009001867A1 (ja) * | 2007-06-26 | 2008-12-31 | Japan Health Sciences Foundation | 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原 |
WO2009059325A2 (en) * | 2007-11-02 | 2009-05-07 | The Johns Hopkins University | Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection |
BRPI0916732B1 (pt) | 2008-07-31 | 2021-06-29 | Glaxosmithkline Biologicals S.A. | Vacina para a prevenção de doença ou infecção relacionada ao papilomavirus humano (hpv) compreendendo partículas semelhantes ao vírus hpv 16 e hpv 18 |
-
2010
- 2010-06-24 EA EA201190327A patent/EA022213B1/ru not_active IP Right Cessation
- 2010-06-24 PE PE2011002154A patent/PE20120563A1/es not_active Application Discontinuation
- 2010-06-24 AU AU2010264695A patent/AU2010264695A1/en not_active Abandoned
- 2010-06-24 CA CA2768172A patent/CA2768172A1/en not_active Abandoned
- 2010-06-24 KR KR1020127001919A patent/KR20120098580A/ko not_active Application Discontinuation
- 2010-06-24 CN CN2010800386242A patent/CN102497880A/zh active Pending
- 2010-06-24 JP JP2012516750A patent/JP2012530505A/ja active Pending
- 2010-06-24 US US13/378,446 patent/US20120087937A1/en not_active Abandoned
- 2010-06-24 SG SG2011093572A patent/SG177269A1/en unknown
- 2010-06-24 BR BRPI1014718A patent/BRPI1014718A2/pt not_active IP Right Cessation
- 2010-06-24 MA MA34546A patent/MA33440B1/fr unknown
- 2010-06-24 MX MX2011013744A patent/MX2011013744A/es not_active Application Discontinuation
- 2010-06-24 EP EP10727731A patent/EP2445525A2/en not_active Withdrawn
- 2010-06-24 WO PCT/EP2010/059024 patent/WO2010149752A2/en active Application Filing
-
2011
- 2011-12-19 DO DO2011000396A patent/DOP2011000396A/es unknown
- 2011-12-20 IL IL217094A patent/IL217094A0/en unknown
- 2011-12-21 ZA ZA2011/09453A patent/ZA201109453B/en unknown
- 2011-12-22 CL CL2011003271A patent/CL2011003271A1/es unknown
-
2012
- 2012-01-04 CO CO12001297A patent/CO6480995A2/es unknown
- 2012-01-16 CR CR20120026A patent/CR20120026A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201109453B (en) | 2012-08-29 |
WO2010149752A3 (en) | 2011-03-31 |
AU2010264695A1 (en) | 2012-01-19 |
KR20120098580A (ko) | 2012-09-05 |
EP2445525A2 (en) | 2012-05-02 |
EA201190327A1 (ru) | 2012-07-30 |
SG177269A1 (en) | 2012-02-28 |
DOP2011000396A (es) | 2012-02-15 |
MX2011013744A (es) | 2012-09-28 |
CA2768172A1 (en) | 2010-12-29 |
WO2010149752A2 (en) | 2010-12-29 |
CL2011003271A1 (es) | 2012-08-31 |
PE20120563A1 (es) | 2012-05-17 |
US20120087937A1 (en) | 2012-04-12 |
CR20120026A (es) | 2012-04-13 |
BRPI1014718A2 (pt) | 2016-04-12 |
MA33440B1 (fr) | 2012-07-03 |
IL217094A0 (en) | 2012-02-29 |
JP2012530505A (ja) | 2012-12-06 |
EA022213B1 (ru) | 2015-11-30 |
CN102497880A (zh) | 2012-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6480995A2 (es) | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
CY1119284T1 (el) | ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs) | |
PH12018501602A1 (en) | Subunit immersion vaccines for fish | |
CO2017004838A2 (es) | Vacunas terapéuticas contra el vph16 | |
AR077396A2 (es) | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS | |
PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
WO2008103819A3 (en) | Chimeric newcastle disease virus vlps | |
MX2015007723A (es) | PARVOVIRUS PORCINO 5ª, METODOS DE USO Y VACUNA. | |
AR101814A1 (es) | Partícula de tipo virus flavivirus | |
PH12015501721A1 (en) | Porcine parvovirus 5b, methods of use and vaccine | |
PH12015502666B1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
EP2949341A4 (en) | RECOMBINANT ANTIGENS OF SWINE CIRCOVIRUS-2 (PCV-2) FOR VACCINATE FORMULATIONS, DIAGNOSIS KIT AND USE THEREOF | |
MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
WO2014140166A3 (en) | Vaccine | |
PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
CL2017001595A1 (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas | |
AR115070A1 (es) | Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso | |
MX360449B (es) | Vacunas para el virus del papiloma humano y metodos para su uso. | |
EP2632942A4 (en) | RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME | |
PE20142102A1 (es) | Metodos y composiciones para tratar enfermedades virales | |
AR109734A1 (es) | Composiciones y métodos de tratamiento de la infección persistente por el virus del papiloma humano (hpv) | |
EA200702077A1 (ru) | Вакцина | |
EA201892488A1 (ru) | Комбинации лечебных вакцин против впч | |
PE20160940A1 (es) | Newcastle recombinante expresando las proteinas s del virus de bronquitis aviar y sus aplicaciones |